Method for displaying active nano antibody by using escherichia coli and application thereof

By using the Ag43 protein and V-type secretion system to display nano-antibodies on E. coli, the problems of high cost and poor stability in nano-antibodies expression and application are solved, and efficient and economical nano-antibodies surface display and presentation are achieved, which has improved its Application potential in the treatment of infectious diseases.

CN119020384APending Publication Date: 2024-11-26HUAZHONG AGRI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411148225.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-21
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art has problems such as high cost, long expression cycle, partial activity loss and poor stability when obtaining and applying nano-antibodies, which limits the application of nano-antibodies in disease treatment.

Method used

Using E. coli as a vector, nanoantibodies are displayed on the bacterial surface using Ag43 protein and V-type secretion system, and efficient expression and purification are achieved through constitutive promoter regulation. Recombinant E. coli is constructed for rapid identification of nanoantibodies and antigen binding and used for Treatment of infectious diseases.

Benefits of technology

Achieve rapid, economical and highly versatile surface display of nano-antibodies. The displayed nano-antibodies are active, able to specifically bind to the target antigen and effectively present them into the body through oral pathways, overcoming the high cost and long cycles of traditional methods. question.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020384A_ABST
    Figure CN119020384A_ABST
Patent Text Reader

Abstract

The invention discloses a method for displaying an active nano antibody by using escherichia coli and application of the method, and belongs to the technical field of biology. The method comprises the following steps: cloning a fusion gene containing a sequence as shown in SEQ ID NO.1, a nano antibody coding sequence and a sequence as shown in SEQ ID NO.2 to an escherichia coli expression vector, and constructing a recombinant expression plasmid; transforming the recombinant expression plasmid into escherichia coli to construct a recombinant strain; and carrying out induced culture or direct culture on the recombinant strain to express the fusion protein, and displaying the nano antibody on the surface of escherichia coli. Compared with a traditional nano antibody preparation method, more time and labor are saved, universality is achieved, and the method can be used for displaying the active nano antibody, constructing and screening a nano library, presenting the nano antibody with neutralizing activity and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a method for displaying active nano antibodies using Escherichia coli and an application thereof. Background Art

[0002] Nanobodies are naturally light chain-deficient antibodies found in the blood of camelids and other animals. Compared with traditional antibodies, they have the advantages of small molecular weight and easy expression and purification. They have become a research hotspot in recent years and have broad application prospects in the biomedical field. Currently, nanobodies have been widely used in disease diagnosis, treatment of infectious diseases, molecular tracing and other fields, such as pathogen detection based on nanobodies, treatment of infectious diseases based on neutralizing nanobodies, etc.

[0003] The main steps of obtaining nano antibodies in the traditional way include: immunization of camels / alpacas, cloning nano antibody genes from peripheral blood lymphocytes of immunized camels / alpacas and constructing gene libraries, library panning and screening, nano antibody expression, purification and identification. Among them, the construction and screening of nano antibody gene libraries are the key steps to obtain nano antibodies. At present, phage display technology, ribosome display technology and yeast surface display technology are mainly used to establish nano antibody gene libraries. These technologies have their own advantages and disadvantages. Phage display technology and ribosome display technology have the advantages of high flux, but the technical difficulty is relatively high. Yeast surface display technology can provide post-translational modification of antibodies, but the disadvantage is that the cycle of yeast culture is long and the cost is high. Bacterial surface display technology overcomes the above shortcomings. It uses the secretion system of bacteria (such as V-type secretion system) or surface protein (such as hemolysin, outer membrane protein) to express the target protein with it, and the target protein can be displayed on the surface of bacteria. Compared with other commonly used methods, it is simple to operate and has a shorter cycle.

[0004] At present, nanobodies are mainly used after being purified through prokaryotic or eukaryotic expression, which has the problems of high cost and inactivity of some nanobodies after prokaryotic expression. The purification of nanobodies is usually carried out in the periplasm of cells to ensure their activity. This is because nanobodies may contain disulfide bonds that affect their correct folding and thus make them unable to be expressed. This is also the current difficulty in the expression and purification of nanobodies.

[0005] Since nano antibodies have a small molecular weight, they have a strong tissue penetration ability, making nano antibodies with neutralizing activity have a good application prospect in neutralizing toxins or treating pathogenic infections. When nano antibodies are used for therapeutic purposes, they need to be expressed and purified first. In addition, some nano antibodies have problems such as excessive metabolic rate or poor stability in the body, which limits the application of nano antibodies to a certain extent. Therefore, the development of a new presentation method for nano antibodies is of great significance for the application of nano antibodies in disease treatment. Summary of the invention

[0006] The purpose of the present invention is to provide a method for quickly and effectively displaying active nanoantibodies using Escherichia coli and its application. This method can be used to quickly identify the binding of nanoantibodies to antigen proteins and is universal for different nanoantibodies. At the same time, recombinant Escherichia coli displaying nanoantibodies with neutralizing activity are constructed for applications such as the treatment of infectious diseases.

[0007] In order to achieve the above object, the technical solution of the present invention is as follows:

[0008] A method for displaying active nanobodies using Escherichia coli comprises the following steps: cloning a fusion gene comprising a sequence shown in SEQ ID NO.1, a nanobody coding sequence, and a sequence shown in SEQ ID NO.2 into an Escherichia coli expression vector to construct a recombinant expression plasmid. The recombinant expression plasmid is transformed into Escherichia coli to construct a recombinant strain. The recombinant strain is induced to culture or directly cultured to express the fusion protein, so that the nanobody can be displayed on the surface of the Escherichia coli.

[0009] The expression of the fusion gene can be regulated by an inducible promoter or a constitutive promoter, and the expression can be regulated by a constitutive promoter by adding a constitutive promoter upstream of the fusion gene. The constitutive promoter is preferably the J23110 promoter, and its sequence is preferably the sequence shown in SEQ ID NO.3.

[0010] The E. coli expression vectors include pQE80, pCDF and the like.

[0011] The Escherichia coli include BL21 and MC4100.

[0012] The method of using Escherichia coli to display active nanobodies also includes the following steps: incubating a fusion protein consisting of an antigen protein targeted by the nanobody and a fluorescent protein with the above-mentioned recombinant strain, and determining the binding status of the antigen protein and the nanobody by detecting with a multifunctional microplate reader or observing with a fluorescence microscope.

[0013] In some embodiments, when the nanobody is an anti-GFP protein nanobody, the construction of the corresponding recombinant expression plasmid is specifically as follows: pQE80 is used as an expression vector, and the fusion gene Ag43-GFPVHH is inserted into pQE80 by homologous recombination to construct a plasmid pQE80-Ag43-GFPVHH. The sequence of the fusion gene Ag43-GFPVHH consists of the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.4-the sequence shown in SEQ ID NO.2, wherein the sequence shown in SEQ ID NO.4 is the GFPVHH coding sequence.

[0014] In some embodiments, when the nanobody is an anti-Shiga toxin 2a B subunit (Stx2a-B) nanobody, the construction of the corresponding recombinant expression plasmid is specifically as follows: pQE80 is used as an expression vector, and the fusion gene Ag43-Stx2aVHH is inserted into pQE80 by homologous recombination to construct a plasmid pQE80-Ag43-Stx2aVHH. The sequence of the fusion gene Ag43-Stx2aVHH consists of the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.5-the sequence shown in SEQ ID NO.2, wherein the sequence shown in SEQ ID NO.5 is the Stx2aVHH coding sequence.

[0015] In some embodiments, when the nanobody is an anti-Shiga toxin 2a B subunit (Stx2a-B) nanobody, the construction of the corresponding recombinant expression plasmid is specifically as follows: pCDF is used as a vector, and the fusion gene Ag43-Stx2aVHH containing the J23110 promoter is inserted into pCDF by homologous recombination to construct a constitutive bacterial surface display Shiga toxin nanobody plasmid pCDF-J23110-Ag43-Stx2aVHH. The sequence of the fusion gene Ag43-Stx2aVHH containing the J23110 promoter is composed of the sequence shown in SEQ ID NO.3-the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.5-the sequence shown in SEQ ID NO.2, wherein the sequence shown in SEQ ID NO.3 is the J23110 promoter, and the sequence shown in SEQ ID NO.5 is the Stx2aVHH coding sequence.

[0016] A nano antibody surface display system is a recombinant strain obtained by the above method.

[0017] The above-mentioned method of using Escherichia coli to display active nanoantibodies or the application of the nanoantibody surface display system include at least one of the following applications: (1) displaying active nanoantibodies; (2) establishing a nanoantibody library and screening for effective nanoantibodies, such as inserting a nanoantibody gene into the expression plasmid in the above method to quickly construct a nanoantibody library and screen for nanoantibodies that can bind to the target antigen; (3) presenting nanoantibodies with neutralizing activity; (4) preparing therapeutic products for diseases caused by infection with antigens targeted by nanoantibodies or microorganisms carrying the antigen, such as preparing therapeutic drugs for diseases caused by infection with Shiga toxin or Shiga toxin-producing bacteria.

[0018] The present invention uses Escherichia coli Ag43 protein to display nano antibodies, which is a V-type secretion system (also called an autotransport system), which can be further inserted into the outer membrane after being secreted into the periplasmic space by means of the Sec secretion system, and then displayed on the bacterial surface. Since the surface transport self-protein Ag43 is first secreted into the periplasmic space, and the periplasmic space is an oxidizing environment, which promotes the formation of disulfide bonds, and some nano antibodies contain disulfide bonds, Ag43 is suitable for the surface display of nano antibodies, and nano antibodies containing disulfide bonds and those not containing disulfide bonds can be displayed and expressed, that is, different nano antibodies have universality. The present invention fuses nano antibodies with Ag43 and expresses them in Escherichia coli. Using common expression plasmids and construction methods, a nano antibody surface display system can be quickly and effectively established, and a strong promoter J23110 that can express exogenous proteins without induction is used to display the target nano antibody at a high level on the surface of recombinant bacteria, and the displayed nano antibodies are active and can specifically bind to the target antigen.

[0019] The method provided by the present invention uses symbiotic Escherichia coli as a vector, uses a constitutive and high-expression level Escherichia coli expression system that is different from the commonly used expression system to express nanobodies, and uses Ag43 protein to display the nanobodies on the bacterial surface. The recombinant Escherichia coli constructed to display the nanobodies with neutralizing activity on the surface also has neutralizing activity. Therefore, compared with the existing preparation and application strategies of nanobodies, which are time-consuming and costly, the present invention provides a simpler, more economical and universal display method for different nanobodies, and this recombinant Escherichia coli can be well presented to humans and animals through oral administration and other methods. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Schematic diagram of anti-GFP protein nanobody displayed on the surface of Escherichia coli.

[0021] Figure 2 Schematic diagram of using fluorescent proteins to verify the display of nanoantibodies on the surface of Escherichia coli.

[0022] Figure 3 Schematic diagram of the recombinant plasmid displaying nanobodies against GFP protein.

[0023] Figure 4 This is the fluorescence detection result of the anti-GFP protein nanobody binding to GFP.

[0024] Figure 5 Schematic diagram of anti-Shiga toxin nanoantibodies with neutralizing activity displayed on the surface of Escherichia coli.

[0025] Figure 6 This is the fluorescence detection result of anti-Shiga toxin nanobody binding to GFPStx2a.

[0026] Figure 7 Schematic diagram of the recombinant plasmid pCDF-J23110-Ag43-Stx2aVHH.

[0027] Figure 8 Fluorescence detection results of anti-Shiga toxin nanoantibodies using Escherichia coli MC4100 as carrier.

[0028] Fig. 9 Schematic diagram of the recombinant plasmid pET28a-Stx2a.

[0029] Fig.10 The results of Shiga toxin activity assay in Vero cells.

[0030] Fig.11 The results of cytotoxicity neutralization experiment. DETAILED DESCRIPTION

[0031] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.

[0032] The raw materials used in the following examples, unless otherwise specified, are conventional commercially available products; the methods used in the following examples, unless otherwise specified, are conventional methods in the art.

[0033] Example 1

[0034] This embodiment provides a method for displaying active nanobodies using Escherichia coli, taking anti-GFP protein nanobodies as an example, including a nanobody surface display system ( Figure 1 ) and the detection of the binding of nanoantibodies to antigen proteins ( Figure 2 ).

[0035] (1) Synthesize the Ag43-GFPVHH fragment consisting of the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.4-the sequence shown in SEQ ID NO.2, and insert it into pQE80 by homologous recombination to construct plasmid pQE80-Ag43-GFPVHH ( Figure 3 ). pQE80-GFPVHH-Ag43 was transformed into Escherichia coli BL21 to obtain a recombinant strain displaying anti-GFP protein nanobody.

[0036] (2) Construction of GFP recombinant plasmid and expression and purification of GFP protein. The coding sequence of GFP protein (SEQ ID NO.6) was cloned into the pQE80 vector by homologous recombination to obtain the recombinant expression plasmid pQE80-GFP. pQE80-GFP was transformed into Escherichia coli BL21 (DE3) to obtain a recombinant strain expressing GFP protein. The BL21 (DE3) strain transformed with the expression plasmid pQE80-GFP was cultured overnight with LB and transferred to 800 mL LB at a dilution of 1:100 and cultured until OD600. nm =0.6, then 1 mM IPTG was added for induction at 16°C overnight, the induced sample was crushed under high pressure, loaded onto a nickel column through a loading pump, and then eluted with different concentrations of imidazole to obtain GFP protein.

[0037] (3) The interaction between fluorescent protein GFP and nanoantibodies displayed on the surface of E. coli was used to verify that the nanoantibodies were successfully displayed on the surface of E. coli. The fluorescent protein GFP was used as the antigen, and the anti-GFP nanoantibody displayed on the surface of E. coli was used as the antibody. The fluorescence intensity was detected to determine whether there was antigen-antibody binding. At the same time, mCherry and plasmid vector pQE80-Ag43 were used as negative controls, and fluorescent protein GFP was used as a positive control. The E. coli BL21 containing pQE80-GFPVHH-Ag43 or pQE80-Ag43 obtained in (1) was cultured to an OD of 600nm =0.6, add fluorescent protein with a final concentration of 10 μg / mL and incubate for 1 hour, and use an enzyme marker to detect the fluorescence value (F) and OD600nm (O). Figure 4 As shown, compared with the control group, the F / O value detected after incubation of E. coli containing pQE80-Ag43-GFPVHH with its target antigen GFP was significantly improved, indicating that the nanoantibody GFPVHH displayed by the E. coli surface display system can specifically recognize and bind to its corresponding antigen GFP, that is, the E. coli surface display system was successfully constructed.

[0038] Example 2

[0039] This example uses the nanobody display method of the present invention to quickly and effectively display nanobodies with toxin neutralizing activity against Shiga toxin on the surface of Escherichia coli ( Figure 5 ), the constructed recombinant Escherichia coli also has toxin neutralizing activity.

[0040] 1. Escherichia coli BL21 as a carrier to display anti-Shiga toxin nanobodies with neutralizing activity

[0041] (1) Construction process of pQE80-Ag43-Stx2aVHH plasmid: An Ag43-Stx2aVHH fragment consisting of the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.5-the sequence shown in SEQ ID NO.2 was synthesized and inserted into pQE80 by homologous recombination to construct the plasmid pQE80-Ag43-Stx2aVHH.

[0042] pQE80-Ag43-Stx2aVHH was transformed into Escherichia coli BL21 (DE3) to obtain a recombinant strain displaying Shiga toxin nanobody.

[0043] (2) Construction of Shiga toxin-GFP fusion protein GFPStx2aB expression plasmid: The fragment consisting of GFP fluorescent protein coding sequence (SEQ ID NO.6)-linker sequence (SEQ ID NO.7)-Stx2aB coding sequence (SEQ ID NO.8) was cloned into the pQE80 vector by homologous recombination to obtain the recombinant expression plasmid pQE80-GFPStx2aB.

[0044] The expression and purification method of Shiga toxin-GFP fusion protein GFPStx2aB is the same as that of fluorescent protein GFP.

[0045] (3) Detection of the binding of Shiga toxin-GFP fusion protein to nanoantibodies displayed on the surface of E. coli: After successfully constructing a recombinant strain displaying Shiga toxin nanoantibodies on the surface, the same method described previously was used to test whether the bacterial surface display system could display Shiga toxin nanoantibodies that bind to antigens. The test results are as follows: Figure 6 As shown, compared with the control group GFP, the F / O value detected after incubation of Escherichia coli BL21 containing pQE80-Ag43-Stx2aVHH with its target antigen GFPstx2aB was significantly improved, indicating that the nanoantibody stx2aVHH displayed by the bacterial surface display system can specifically recognize and bind to its corresponding antigen GFPstx2aB, that is, the bacterial surface display system can successfully display nanoantibodies against Shiga toxin.

[0046] 2. E. coli MC4100 as a carrier to display anti-Shiga toxin nanobodies with neutralizing activity

[0047] (1) Construction of a strain displaying anti-Shiga toxin nanoantibodies using Escherichia coli MC4100 as a carrier: In order to overcome the disadvantage that the commonly used expression plasmid pQE80 requires IPTG induction, which leads to high cost and time-consuming nanoantibody expression and display in actual production applications, the promoter element J23110 that does not require induction was used to construct a constitutive Escherichia coli surface displaying anti-Shiga toxin nanoantibody plasmid pCDF-J23110-Ag43-Stx2aVHH.

[0048] A J23110-Ag43-Stx2aVHH fragment consisting of the sequence shown in SEQ ID NO.3-the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.5-the sequence shown in SEQ ID NO.2 was synthesized and inserted into pCDF by homologous recombination to construct pCDF-J23110-Ag43-Stx2aVHH ( Figure 7 ).

[0049] The plasmid pCDF-J23110-Ag43-Stx2aVHH was electroporated into the MC4100 strain to obtain a recombinant strain displaying anti-Shiga toxin nanobodies.

[0050] (2) Fluorescence detection of anti-Shiga toxin nanobodies with E. coli MC4100 as carrier: In order to explore whether the bacterial surface display system can display anti-Shiga toxin nanobodies with antigen-binding activity on the surface of E. coli MC4100, the same method as previously described for verifying the surface display system using fluorescent proteins was adopted. After the E. coli MC4100 strain containing pCDF-J23110-Ag43-Stx2aVHH was incubated with its corresponding antigen GFPstx2aB, the fluorescence detection results of the microplate reader were as follows: Figure 8 As shown, the fluorescence result F / O value was significantly higher than that of the control group incubated with GFP, indicating that the MC4100 strain transformed with pCDF-J23110-Ag43-Stx2aVHH had excellent specific recognition and binding ability toxins.

[0051] Example 3

[0052] (1) Construction of Shiga toxin Stx expression plasmid: The Shiga toxin Stx2a fragment (SEQ ID NO.9) was cloned into the plasmid pET28a by homologous recombination to construct the expression plasmid pET28a-Stx2a ( Fig. 9 ).

[0053] (2) Purification of Shiga toxin Stx: ​​The BL21 (DE3) strain transformed with the expression plasmid pET28a-Stx2a was inoculated into LB and cultured overnight by shaking, then transferred to 500 mL LB at a ratio of 1:100 and cultured for 2 h. After that, 1 mM IPTG was added and induced at 16°C for 16 h. Purification was performed using the method described previously.

[0054] (3) Determination of Shiga toxin Stx activity using Vero cells: The purified Shiga toxin Stx was diluted with sterile PBS at different times, with the concentrations of 250 μg / mL, 125 μg / mL, 72.5 μg / mL, 36.25 μg / mL, and 18.125 μg / mL, respectively. 10 μL was taken and incubated with Vero cells (1×10 4 Each well contained 90 μL of cell culture medium) in a 96-well plate at 37°C and 5% CO2 for three days, and the cell survival rate was calculated after adding CCK-8 for color development. Fig.10 As shown, the survival rate of Vero cells incubated with Stx was significantly reduced compared with the non-toxic flagellin Flic control, indicating that the purified Shiga toxin Stx was toxic to Vero cells and the Vero cell Shiga toxin cytotoxicity model was successfully established.

[0055] (4) The neutralizing activity of the anti-Shiga toxin nanoantibody displayed on the surface of Escherichia coli was determined using the constructed Vero cell Shiga toxin cytotoxicity model: the MC4100 strain containing pCDF-J23110-Ag43-Stx2aVHH or MC4100 at a ratio of 1:100 cultured overnight was transferred to 5 mL LB and shaken at 37°C for 6 h. The OD600nm was adjusted to 2. The Shiga toxin concentrations that caused 90% cell mortality (300 μg / mL) and the cell median lethal dose (18.75 μg / mL) were used to incubate the bacterial solution at OD600nm = 2 and OD600nm = 0.2 of the above strain at 37°C for 3 h, and then filtered twice with a 0.22 μm filter. Finally, 10 uL of the resulting mixture was mixed with Vero cells (cell number 1×10 4 Each well contained 90 μL of cell culture medium) in a 96-well plate at 37°C and 5% CO2 for three days, and the cell survival rate was calculated after adding CCK-8 for color development. Fig.11 As shown, it was demonstrated that the anti-Shiga toxin nanobody displayed on the surface of Escherichia coli had neutralizing activity.

[0056] The above embodiments are only used to help illustrate the present invention. The implementation methods of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A method for displaying active nanobodies using Escherichia coli, characterized in that: The method comprises the following steps: cloning a fusion gene comprising a sequence shown in SEQ ID NO.1, a nanobody coding sequence, and a sequence shown in SEQ ID NO.2 into an Escherichia coli expression vector to construct a recombinant expression plasmid; transforming the recombinant expression plasmid into Escherichia coli to construct a recombinant strain; inducing or culturing the recombinant strain to express the fusion protein, and displaying the nanobody on the surface of the Escherichia coli.

2. The method for displaying active nanobodies using Escherichia coli according to claim 1, characterized in that: The expression of the fusion gene is regulated by an inducible promoter or a constitutive promoter.

3. The method for displaying active nanobodies using Escherichia coli according to claim 2, characterized in that: By adding a constitutive promoter upstream of the fusion gene, its expression is regulated by the constitutive promoter.

4. The method for displaying active nanobodies using Escherichia coli according to claim 2, characterized in that: The constitutive promoter is the J23110 promoter.

5. The method for displaying active nanobodies using Escherichia coli according to claim 1, characterized in that: The E. coli expression vectors include pQE80 and pCDF.

6. The method for displaying active nanobodies using Escherichia coli according to claim 1, characterized in that: The Escherichia coli include BL21 and MC4100.

7. The method for displaying active nanobodies using Escherichia coli according to claim 1, characterized in that: The following steps are also included: The fusion protein consisting of the antigen protein targeted by the nanobody and the fluorescent protein is incubated with the recombinant strain, and the binding status of the antigen protein and the nanobody is determined by detection with a multifunctional microplate reader or observation under a fluorescence microscope.

8. The method for displaying active nanobodies using Escherichia coli according to claim 1, characterized in that: When the nanobody is an anti-GFP protein nanobody, the corresponding recombinant expression plasmid is constructed as follows: pQE80 is used as an expression vector, and the fusion gene Ag43-GFPVHH is inserted into pQE80 by homologous recombination to construct a plasmid pQE80-Ag43-GFPVHH; the sequence of the fusion gene Ag43-GFPVHH is composed of the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.4-the sequence shown in SEQ ID NO.2; Or when the nanobody is an anti-Shiga toxin 2a B subunit nanobody, the corresponding recombinant expression plasmid is constructed as follows: pQE80 is used as an expression vector, and the fusion gene Ag43-Stx2aVHH is inserted into pQE80 by homologous recombination to construct a plasmid pQE80-Ag43-Stx2aVHH; the sequence of the fusion gene Ag43-Stx2aVHH is composed of the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.5-the sequence shown in SEQ ID NO.2; Or when the nanobody is an anti-Shiga toxin 2a B subunit nanobody, the corresponding recombinant expression plasmid is constructed as follows: using pCDF as a vector, the fusion gene Ag43-Stx2aVHH containing the J23110 promoter is inserted into pCDF by homologous recombination to construct the plasmid pCDF-J23110-Ag43-Stx2aVHH; the sequence composition of the fusion gene Ag43-Stx2aVHH containing the J23110 promoter is the sequence shown in SEQ ID NO.3-the sequence shown in SEQ ID NO.1-the sequence shown in SEQ ID NO.5-the sequence shown in SEQ ID NO.

2.

9. A nanobody surface display system, characterized in that: The recombinant strain is obtained by the method according to any one of claims 1 to 8.

10. Use of the method according to any one of claims 1 to 8 or the nanobody surface display system according to claim 9, characterized in that: The invention comprises at least one of the following applications: (1) displaying active nanobodies; (2) establishing a nanobody library and screening nanobodies; (3) presenting nanobodies with neutralizing activity; (4) preparing therapeutic products for diseases caused by infection with antigens targeted by nanobodies or microorganisms carrying the antigens.